Fluorescence in situ hybridization or ribonucleic acid sequencing technologies should be recommended for ALK-negative patients who was suspected for IMT.[13] Also, abnormalities not implicating the ALK gene are very rare in uterus tumors, such as TIMP3-RET, TIMP3-ROS1, and FN1-ROS1. This evidence concerns the gene ROS1 and inflammatory myofibroblastic tumor.